Breast Cancer Study

STUDY IN VIVO
A fresh capillary blood sample was taken at a time according to protocol to be examined as live
blood sample under Phase Contrast,
Dark Field and Direct Illumination at 40 X, 40 X plus 3.5 X
and 17 X magnifications. A second

drop was taken for Clot Retraction Analysis. The results are
recorded on the data sheets included in the report.
CASE STUDY
Case Study
#
1.
A female age 37 with
the following condition;
1. Breast Cancer metastasized into the bones (ribs, lumbar and thoracic vertebrae)
2. History of bilateral mastectomy and chemotherapy
3. History of bilateral breast implants
4. Macrocytic anemia
Note: The patient presented a bact
erial infection the day when the sample was taken adding to the
baseline pathology.
The pages that follow record data compiled each day.
CASE STUDY OF Covalent Silver  IN CANCER PATIENT IGWP

C1.596
Page
1
ANALYSIS OF THE EFFECTS OF Covalent Silver  IN BLOOD
BEFORE AND DURING TREATMENT IN VIVO
While in the clinic the patient received Covalent Silver as well as a combination
of therapies used to
enhance her treatment program.
Protein linkage was elevated at the beginning, followed by a sustained low level towards the end of the
study.
Comparing this pattern with the rouleaux formation that was elevated at the beginning and lo
w at the
end, it can be assumed that this resulted in diminished erythrocyte aggregation. The readings
immediately after the
Covalent Silver dosage showed little increase in these three patterns. This result may be due to a pH
variance stimulated by Covale
nt Silver. The in vitro study showed an opposite effect, however this was
not a fresh sample and therefore could have been the effect of the metabolism with Covalent Silver. On
arrival the patient’s poikilocytosis and anisocytosis were seen to be less as c
ompared to following
readings. The second reading recorded (+ +) this being before the administration of the first dose of the
Covalent Silver. Therefore it can be assumed that there is no relationship between Covalent Silver  and
progressive anemia. Coval
ent Silver therefore, does not affect healthy red cells in vivo. The anemia
could have had an effect on the rouleaux and aggregation.
Acanthocytes were always present in low amounts. Acanthocytes are related to viral activity and there
was No
significant
change
before and after the first, second and third doses. Contrary to the in vitro
study, Covalent Silver does not have the lipoprotein lysis action as in vivo.
The amount of schistocytes was variable during the different stages of the monitor
ing, which was lower
towards the end as compared to the beginning. The penultimate reading was a high (+ + +). The
toxicity in the blood was varied and to establish a more accurate conclusion, farther tests should be
performed. By comparing the first and
‘last sample, it is seen that liver stress decreased. This was
measured by the presence of spicules. There was a small increase immediately after the first dose of
Covalent Silver , thereafter stabilized at a low level. The sample was viable for three days
. The roulette
average remained the same as the control as well as the aggregation (+ + +), with predominance in the
area where the Covalent Silver  made contact with the blood. Acanthocytes and schistocytes were
always present in elevated amounts (+ + +).
There was no variation in the cholesterol level. There was
a higher amount of uric acid as compared to the other two samples
Acanthocytes and schistocytes were always present in elevated amounts (+ + +).
There was no variation in the cholesterol level.
Th
ere was a higher amount of uric acid as compared to the other two samples.
More spicules present than in the other two samples.
Target cells were the same.
CASE STUDY OF COVALENT SILVER  IN CANCER PATIENT IGWP

C1.596
Page 2.
No fungus seen by the second day, and no further changes were observed.
The somatide cycle began with rod forms, Spores appeared the second day and were present until the
last day.
From the beginning the immune system was under attack. Phagocy
tes with preserved cytoplasm
showed no
activity. They appeared to be filled fungus, although there was an absence of fungus in the plasma.
Spherocytes appeared in elevated amounts at all times (+ + +).
There was no thrombosis tendency at all, which was dif
ferent from the control, but the same as 1:10
dilution.
There was no bacterial activity.
Crenocytes were present from the first day, vacuolae dendroids appeared on the last day. There was
presence of multiple crystals, at the side of the Covalent Silver .
CASE STUDY OF COVALENT SILVER  IN CANCER PATIENT IGWP

C1.596 Page 3.
Category 1
Dilution 1:10
The sample was viable for three days, there was less rouleaux formation than the control, and more
aggregation than the other two samples, especially in the area where the Covalent Silver  made
contact with the blood.
The first
day Acanthocytes
were
seen in elevated amounts (+ + +), compared to the control that had
(+). In this sample, there were more schistocytes seen than in the control.
There were more spicules seen at all times, compared to the control.
No variation in chole
sterol crystal levels. There was slightly more uric acid excess present than in
the control.
The same elevated levels of Target cells were seen. By the second day there was no fungus present
in the plasma; they were inside the Phagocytes, up to four in eac
h one.
Rod forms of the somatide cycle were seen the first day. The second day there was only nonpathogenic
forms. By the third day there were rod and mycelial forms. On the fourth day rod,
mycelial and asci forms were seen. There was only bacterial activi
ty as the rest of the sample was no
longer viable.
The immune system was under attack at all times, the condition of the cytoplasm was better than in
the control. The activity was really slow.
Spherocytes were seen immediately after adding Covalent Silver
. This probably relates to
toxicity that Covalent Silver  has at this dilution when applied directly to a drop of live blood.
There was no thrombocyte aggregation. The control fluctuated.
Bacterial activity went from zero to (+ + +), the control that went
from (+ + +) to (+).
Elevated amounts of Crenocytes were present at all times. There were vacuolae den droids present on the after.
CASE STUDY OF COVALENT SILVER  IN CANCER PATIENT IGWP

C1.596
Page 4.
Category 2
The second category (control, 1:50, 1:100) was analyzed by comparing the three samples during the three
day survival time. The control was the only sample that survived for only two days. In this section control,
1:50, and 1:100 dilut
ions are compared.
This sample was viable for two days. Rouleaux formation reduced from (+ +) to 0. Aggregation reduced
from (+) to 0. Both rouleaux and aggregation had a better evolution in this sample than in the other two
samples with Covalent Silver .
The lower dilutions were not effective in changing the pH.
The control showed a minimum presence of Acanthocytes as compared to the other two dilutions.
Acanthocytes represent viral activity and/or lack of beta lipoproteins, this indicates the use of 1 ;50
and
1:100 dilutions are not effective in decreasing viral activity and stabilizing the beta lipoproteins.
The schistocytes had an uncertain behavior, because in the control there was (+) present the first day. The next
day the sample presented 100%
Schistocytes and were less present in the 1:100 and 1:50 in that order.
The fibrin spicules were always present, mainly in the 1:100, less in the 1:50 dilution and even less in the
control.
Chylomicron were present in 1:100 dilution (+ + +), especially in
the area of contact between the blood and
EionSilver  Solution.
The 1:100 dilution presented more cholesterol than in the 1:50 dilution and than the control.
Uric Acid Crystals were seen in the three samples, one (+) in average. The other samples showed a
slight
tendency to increase, this tendency was not seen in the 1: 100.
In the control, protoplasts were seen only once by the second day; this was not seen in the 1:50 nor in the
1:100 case study.
CASE STUDY OF COVALENT SILVER   IN CANCER PATIENT IGWP

C1.596
Page
5